List of Excipients in Branded Drug NAMZARIC

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1207	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1207	ETHYLCELLULOSE
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1207	FD&C BLUE NO. 1
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1207	FERRIC OXIDE YELLOW

Namzaric Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Namzaric is a fixed-dose oral combination of memantine hydrochloride extended release and donepezil hydrochloride immediate release for moderate-to-severe Alzheimer’s disease. Its commercial value is tied to multiparticulate release control, capsule compatibility, dose-ratio flexibility, and the ability to maintain adherence in patients already receiving the two active ingredients separately. The strongest excipient opportunities are in modified-release coating systems, capsule-fill uniformity, sprinkle performance, taste control, and lower-cost alternatives to proprietary manufacturing processes.

What is Namzaric and how is it formulated?

Namzaric combines two established Alzheimer’s disease medicines in a once-daily capsule:

Attribute	Namzaric
Active ingredients	Memantine hydrochloride extended release; donepezil hydrochloride immediate release
Dosage form	Hard gelatin capsule containing multiparticulate drug products
FDA approval	September 23, 2014
Indication	Moderate-to-severe dementia of the Alzheimer’s type
Strengths	7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, and 28 mg/10 mg
Originator	Forest Laboratories, later acquired by Actavis/Allergan and ultimately AbbVie
Administration	Once daily, generally in the evening
Administration flexibility	Capsule may be opened and sprinkled on applesauce without chewing, according to labeling
Regulatory pathway	Approved under NDA 206439

The formulation separates the release profiles of the two drugs. Donepezil is delivered as an immediate-release component, while memantine is delivered in an extended-release form. This design permits once-daily administration while preserving the established pharmacology of each active ingredient.

Namzaric’s prescribing information identifies excipients associated with multiparticulate manufacture and hard-capsule delivery, including sugar spheres, povidone, talc, hypromellose, ethylcellulose, polyethylene glycol, gelatin, titanium dioxide, and capsule colorants. The precise excipient composition and colorant system vary by strength and should be confirmed against the current FDA labeling and chemistry, manufacturing, and controls documentation (U.S. Food and Drug Administration, 2014).

What excipients are used in Namzaric?

The principal excipient functions are release control, pellet formation, coating adhesion, capsule manufacture, and product identification.

Excipient or excipient class	Primary function in Namzaric-type formulation	Commercial relevance
Sugar spheres	Inert pellet cores or multiparticulate substrate	Supports uniform drug layering and coating
Povidone	Binder and drug-layering aid	Affects pellet robustness and process yield
Talc	Anti-tacking and coating-process aid	Can reduce agglomeration during fluid-bed coating
Hypromellose	Film former or protective coating polymer	Supports drug-layer integrity and coating uniformity
Ethylcellulose	Water-insoluble release-control polymer	Central to extended-release memantine performance
Polyethylene glycol	Plasticizer and coating modifier	Improves film flexibility and reduces brittleness
Gelatin	Hard-capsule shell material	Determines shell mechanical properties and compatibility
Titanium dioxide	Opacifier and colorant	Supports light protection and product identification
Iron oxides and FD&C colorants	Capsule identification	Helps distinguish strength and reduce medication errors

The most strategically important excipient is the release-controlling polymer system. A generic or reformulated product must deliver memantine over the required period while preventing premature release, excessive variability, and dose dumping. The coating composition, weight gain, pore structure, curing conditions, and pellet-size distribution can materially affect in vitro and in vivo performance.

How does the Namzaric release system create formulation opportunities?

The core opportunity is a multiparticulate platform that preserves immediate-release donepezil exposure while extending memantine release.

Extended-release memantine pellets

Ethylcellulose-based coatings are commercially attractive because they can be processed through aqueous or organic coating systems, depending on the selected grade and formulation design. Development variables include:

• Polymer grade and viscosity
• Coating weight gain
• Plasticizer concentration
• Pore-former selection
• Pellet diameter
• Drug-layer thickness
• Coating curing conditions
• Storage humidity and temperature

A manufacturer can seek a lower-cost or higher-throughput alternative using a different ethylcellulose grade, a polymer blend, or a fully aqueous coating process. The principal technical risk is bioequivalence. A change that appears minor in coating composition can alter the entire plasma-concentration profile of memantine.

Immediate-release donepezil pellets

Donepezil can be formulated through drug layering, powder layering, or direct incorporation into a multiparticulate blend. The key commercial objectives are content uniformity, low friability, minimal segregation, and rapid dissolution.

The formulation must also prevent interaction between the immediate-release donepezil population and the extended-release memantine population during manufacture and storage. Differences in particle density, size, electrostatic behavior, or coating friction can produce blend segregation and fill-weight variability.

Sprinkle performance

The sprinkle claim creates a separate development target. A formulation intended to be opened and sprinkled on soft food must demonstrate:

• Dose recovery after transfer
• No significant pellet adhesion to the capsule or food
• No pellet crushing during handling
• Acceptable taste and mouthfeel
• Maintenance of the memantine release profile
• Stability after short-term exposure to food moisture

Sprinkle-compatible multiparticulates are commercially valuable for patients with swallowing difficulty, caregivers administering medicines, and institutional settings.

What commercial opportunities exist for Namzaric excipients?

The market opportunity is divided between generic manufacturing, excipient supply, reformulated products, and contract development.

1. Generic Namzaric manufacturing

The most direct opportunity is supply to manufacturers developing abbreviated new drug applications. Generic competition requires reliable sources for:

• Ethylcellulose or equivalent release-control polymers
• Hypromellose coating grades
• Pharmaceutical-grade sugar spheres
• Povidone binders
• Talc suitable for coating processes
• Polyethylene glycol plasticizers
• Hard-gelatin capsule shells
• Strength-specific colorant systems

A supplier that can provide consistent particle-size distribution, low microbial burden, validated elemental-impurity control, and reliable global supply can gain an advantage even when its excipient is pharmaceutically equivalent to a widely used material.

2. Excipient substitution

Excipient substitution can lower cost or reduce supply-chain concentration. Potential substitution strategies include:

• Replacing a proprietary coating system with standard ethylcellulose and pore-former combinations
• Using a directly compressible or spray-dried binder in place of conventional povidone grades
• Replacing titanium dioxide with an alternative opacifier where regulatory and visual requirements permit
• Moving from gelatin to hypromellose capsules for vegetarian, religious, or supply-chain reasons
• Using alternative colorant systems to simplify global registration

The substitution must preserve dissolution, stability, capsule performance, and bioequivalence. A formulation that requires extensive clinical bridging may lose the economic advantage of a lower-cost excipient.

3. 505(b)(2) reformulation

A 505(b)(2) product could target a clinically or commercially meaningful difference, such as:

• A capsule-free sprinkle product
• An orally disintegrating multiparticulate formulation
• A liquid or suspension formulation
• A reduced-swallowing-burden product
• A formulation with improved moisture protection
• A longer shelf life
• A product with an alternative capsule shell
• A product optimized for feeding-tube administration

The 505(b)(2) route is more relevant to meaningful formulation changes than to a routine composition change that can be supported through an ANDA. The regulatory value depends on whether the new dosage form addresses a recognized limitation of the reference product and whether the sponsor can support the bridge to the approved combination.

4. Contract development and manufacturing

Specialized contract manufacturers can offer development packages covering:

• Drug-layered pellet production
• Fluid-bed coating
• Multiparticulate blending
• Capsule filling
• Sprinkle testing
• Dissolution method development
• Scale-up and process validation
• Stability studies
• ANDA CMC documentation

The highest-value manufacturing capability is not basic capsule filling. It is reproducible control of pellet coating and blend uniformity across four memantine dose strengths.

What formulation patents protect Namzaric?

Namzaric patent protection is directed primarily to the combination product, dosage form, release profile, and related pharmaceutical compositions rather than to the basic pharmacology of donepezil or memantine. Donepezil and memantine were established active ingredients before Namzaric approval.

The relevant intellectual-property categories are:

IP category	Commercial subject matter	Risk to a competitor
Combination composition	Co-formulation of donepezil and memantine	May affect fixed-dose combination products
Modified release	Extended-release delivery of memantine	Can constrain coating and pellet designs
Dosage form	Capsule containing distinct release populations	May affect multiparticulate architecture
Method of use	Treatment of moderate-to-severe Alzheimer’s disease	May affect labeling and induced-infringement risk
Manufacturing process	Drug layering, coating, blending, or capsule filling	Usually narrower and process-dependent
Sprinkle administration	Opening capsule and administering on soft food	May affect product instructions and labeling

A freedom-to-operate review must compare the proposed formulation against issued claims, not merely against the marketed product. A different coating polymer does not automatically avoid a claim if the claim is written functionally or covers a broad combination of immediate-release and extended-release particles.

When did Namzaric lose regulatory exclusivity?

Namzaric received FDA approval in 2014 as a new combination of previously approved active ingredients. The product’s regulatory exclusivity was therefore distinct from the patent estate for the combination and formulation.

The principal timing points are:

Milestone	Date or status
FDA approval	September 23, 2014
Three-year combination-product exclusivity	Generally associated with the approval of a new clinical investigation supporting the combination
ANDA timing	Dependent on applicable listed patents and exclusivity
Generic competition	FDA-approved generic versions have entered the U.S. market
Current commercial position	Branded Namzaric competes with generic fixed-dose products and separate donepezil/memantine therapy

The FDA Orange Book remains the controlling source for listed patents, pediatric exclusivity, and generic-approval timing. Patent expiration should be assessed patent by patent because formulation and method-of-use claims can expire at different times and may have different enforceability profiles (U.S. Food and Drug Administration, n.d.-a).

What is the Orange Book status of Namzaric?

Namzaric is an NDA product subject to Orange Book listing analysis. The relevant questions for a generic applicant are:

1. Which patents are listed against NDA 206439?
2. Which listed patents claim the drug substance, formulation, method of use, or drug product?
3. Which patents are eligible for Paragraph IV certification?
4. Are any patents expired, delisted, or subject to a regulatory-use carve-out?
5. Does the proposed ANDA label omit the patented use?
6. Has the reference sponsor filed patent litigation within the statutory period?

A Paragraph IV certification can trigger patent litigation if the reference sponsor or patent owner files suit within the applicable statutory window. The resulting stay can delay ANDA approval, although the duration and effect depend on the timing of certification, litigation, patent expiration, and any settlement.

Which companies are challenging Namzaric?

Generic competition has focused on manufacturers capable of reproducing the fixed-dose combination rather than on biosimilar developers. Namzaric is a small-molecule product, so it does not face biosimilar competition under the Public Health Service Act. The relevant competitors are ANDA applicants and manufacturers selling separate generic donepezil and memantine products.

Competitive pressure comes from four product types:

• Generic fixed-dose memantine/donepezil capsules
• Generic donepezil plus generic memantine prescribed separately
• Branded Namzaric
• Alternative Alzheimer’s disease therapies, including monoclonal antibody products for selected patients

Public company-specific Paragraph IV and settlement conclusions require a current review of FDA ANDA records, court dockets, and Orange Book litigation information. The commercial impact is greatest where a generic fixed-dose product can match Namzaric’s once-daily convenience and sprinkle administration.

How strong is the Namzaric patent estate?

The estate is strategically stronger in formulation and combination claims than in active-ingredient claims. Donepezil and memantine themselves are mature small molecules with broad generic availability. The defensible value of Namzaric therefore depends on:

• Breadth of the combination claims
• Scope of the extended-release memantine claims
• Coverage of multiparticulate capsules
• Validity of functional dissolution limitations
• Enforceability of method-of-use claims
• Ability of a generic applicant to design around the coating system
• Remaining patent term and Orange Book listing status

A formulation patent is more commercially meaningful when it captures the product’s required performance rather than a narrow manufacturing recipe. At the same time, functional release claims may face validity challenges involving written description, enablement, obviousness, or anticipation.

What manufacturing and IP barriers affect generic launch?

The principal barriers are technical and regulatory rather than raw-material availability.

Manufacturing barriers

• Maintaining uniform coating weight across multiple pellet populations
• Preventing pellet fracture during blending and encapsulation
• Controlling dissolution after scale-up
• Matching food-effect behavior
• Preserving sprinkle performance
• Managing capsule shell moisture
• Demonstrating four-strength bioequivalence or proportionality

IP barriers

• Combination-product claims
• Extended-release formulation claims
• Method-of-use claims
• Patent claims covering capsule contents or release profiles
• Potential litigation after Paragraph IV certification
• Settlement terms that restrict launch timing or manufacturing methods

A generic launch strategy should prioritize a formulation that is demonstrably bioequivalent but structurally distinct from the reference product. The best design-around candidates usually change the coating architecture, pellet substrate, capsule shell, or manufacturing sequence while preserving the required release profile.

How does Namzaric compare with separate donepezil and memantine products?

Factor	Namzaric	Separate generic products
Dosing	One capsule once daily	Two products and potentially different schedules
Adherence	Simplifies administration	More complex regimen
Flexibility	Limited to available fixed strengths	Allows independent titration
Cost	Historically branded premium; now generic competition	Usually lower acquisition cost
Formulation	Combined immediate- and extended-release system	Separate dosage forms
Caregiver burden	Lower for patients stabilized on both drugs	Higher medication-management burden
Substitution risk	Requires fixed-dose product availability	Broad generic supply
Commercial advantage	Convenience and single-prescription management	Price and dosing flexibility

The fixed-dose combination is most attractive for patients who are already stable on both active ingredients and benefit from simplified administration. Separate therapy remains more flexible during titration and when adverse effects require adjustment of only one component.

Key Takeaways

• Namzaric is a once-daily capsule combining immediate-release donepezil with extended-release memantine.
• The main excipient value lies in multiparticulate coating, pellet integrity, capsule compatibility, and sprinkle performance.
• Ethylcellulose, hypromellose, polyethylene glycol, povidone, talc, and sugar spheres are central to a Namzaric-type formulation strategy.
• Generic opportunities include excipient substitution, coating-process optimization, contract manufacturing, and fixed-dose capsule supply.
• A 505(b)(2) strategy is more commercially credible for a clinically differentiated dosage form than for a routine excipient change.
• Namzaric is a small-molecule product and faces generic, not biosimilar, competition.
• The key IP issues are combination, modified-release, dosage-form, method-of-use, and manufacturing claims.
• The Orange Book and current FDA patent records control the assessment of listed patents, Paragraph IV exposure, and launch timing.
• Manufacturing risk centers on dissolution matching, coating uniformity, sprinkle performance, and scale-up across four strengths.

FAQs

Can Namzaric excipients be changed without a new clinical trial?

Possibly. A generic applicant may use a different excipient system if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and stability requirements. A clinically differentiated reformulation may require a 505(b)(2) application.

Is Namzaric a biologic subject to biosimilar competition?

No. Namzaric contains the small molecules memantine hydrochloride and donepezil hydrochloride. Competition proceeds through generic-drug pathways rather than biosimilar approval pathways.

Which excipient has the greatest impact on Namzaric performance?

The release-controlling polymer system has the greatest impact because it determines memantine dissolution and exposure. Ethylcellulose concentration, coating weight, plasticizer level, pore structure, and curing conditions are major variables.

Can a competitor avoid Namzaric patents by using a different polymer?

Not necessarily. Avoidance depends on the wording of the issued claims. A patent may cover a broad functional release profile, a combination of immediate- and extended-release particles, or a specific dosage-form architecture rather than a named polymer alone.

What is the strongest commercial alternative to Namzaric?

For price-sensitive markets, separate generic donepezil and memantine are the strongest alternatives. For adherence-focused markets, a generic fixed-dose multiparticulate capsule that matches Namzaric’s once-daily and sprinkle characteristics is the closest substitute.

References

1. U.S. Food and Drug Administration. (2014). Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application process.
4. U.S. Food and Drug Administration. (n.d.-c). 505(b)(2) applications.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Maryland: U.S. Pharmacopeial Convention.